Reviewing Insmed (NASDAQ:INSM) & Ceapro (OTCMKTS:CRPOF)

Insmed (NASDAQ:INSM) and Ceapro (OTCMKTS:CRPOF) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk and Volatility

Insmed has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Ceapro has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares Insmed and Ceapro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-252.01%	N/A	-54.43%
Ceapro	-69.60%	-20.30%	-18.07%

Earnings & Valuation

This table compares Insmed and Ceapro”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$342.96 million	36.79	-$749.57 million	($5.55)	-12.71
Ceapro	$7.14 million	1.86	-$3.49 million	($0.06)	-2.83

Ceapro has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Insmed and Ceapro, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	0	0	16	0	3.00
Ceapro	0	0	0	0	0.00

Insmed currently has a consensus price target of $83.67, suggesting a potential upside of 18.63%. Given Insmed’s stronger consensus rating and higher possible upside, equities analysts plainly believe Insmed is more favorable than Ceapro.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Ceapro

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.